The role of paliperidone extended release for the treatment of bipolar disorder

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 181-189

  Marino, Jehan ^a   English, Clayton ^b   Caballero, Joshua ^a   Harrington, Catherine ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Bipolar disorder; Clinical efficacy; Paliperidone ER; Safety

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CHLORPROMAZINE; FLUOXETINE PLUS OLANZAPINE; KETOCONAZOLE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIMETHOPRIM; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; AREA UNDER THE CURVE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; EMBASE; EXTENDED RELEASE FORMULATION; EXTRAPYRAMIDAL SYNDROME; HEADACHE; HUMAN; HYPERSALIVATION; INCREASED APPETITE; INFORMATION RETRIEVAL; INSOMNIA; INTRAMUSCULAR DRUG ADMINISTRATION; LIQUID; MAINTENANCE THERAPY; MANIA; MEDLINE; MIXED MANIA AND DEPRESSION; MONOTHERAPY; MUSCLE HYPERTONIA; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84860877345     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S20675     Document Type: Review

References (35)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543-552.
2. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-251.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.
4. Ostacher MJ, Perlis RH, Nierenberg AA, et al. Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2010; 167(3):289-297.
5. Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry. 2010;71(3):296-303.
6. Perlis RH, Uher R, Ostacher M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry. 2011;68(4):351-360.
7. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 159(Suppl 4):1-50.
8. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7): 870-886.
9. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225-255.
10. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306-1315.
11. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard FirstEpisode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099-2107.
12. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105(3):164-172.
13. Vieta E, Sanchez-Moreno J. Acute and long-term treatment of mania. Dialogues Clin Neurosci. 2008;10(2):165-179.
14. TM (paliperidone) extended-release tablets [package insert]. Titusville, NJ; 2007.
15. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994; 55 Suppl:5-12.
16. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1-2): 57-73.
17. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000; 68(1):29-39.
18. Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994;114(1):9-23.
19. Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics, dopamine (D2) and serotonin 5HT(2A) receptor occupancy of paliperidone in healthy subjects. Clin Pharmacol Ther. 2005;79:P74-P74.
20. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1): 79-104.
21. Corena-McLeod Mdel P, Oliveros A, Charlesworth C, et al. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res. 2008;3(1233): 8-19.
22. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769-779.
23. Cleton A, Rossenu S, Vermeulen A, et al. A pharmacokinetic model to document the interconversion between paliperidone's enantiomers [abstract]. Clin Pharmacol Ther. 2006;79(2):55.
24. Rossenu S, van de Vliet I, Cleton A, et al. A pharmacokinetic model to document the interconversion between the enantiomers of paliperidone [abstract]. Biol Psychiatry. 2006;59(8):223S.
25. Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther. 2009;47(10):606-616.
26. Dunbar F, Chue P, Fu D, Huang Q, Franc M, Cohen N. Impact of CYP2D6 metabolizer phenotype on the safety profile of paliperidone ER. The Society of Biological Psychiatry 62nd Annual Scientific Convention, San Diego, California, May 17-19, 2007.
27. Cleton A, Rossenu S, Boom S, et al. Evaluation of the pharmacokinetics of paliperidone extended release tablets in healthy elderly subjects. Presented at the 3rd Pharmaceutical Sciences World Congress. Amsterdam, The Netherlands; 2007.
28. Chirita V. A safety and pharmacokinetic study of ER OROS paliperidone in pediatric patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2011 [updated June 6, 2011]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00796081. NLM identifier: NCT00796081. Accessed March 16, 2012.
29. Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry. 2009;42(4):158-163.
30. Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol. 2009;24(7):532-539.
31. De Leon J, Wynn G S N. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51(1):80-88.
32. Berwaerts J, Xu H, Nuamah I, Lim P, Hough D. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord. 2012;136(1-2):e51-e60.
33. Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo and activecontrolled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010;12(3):230-243.
34. Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord. 2011; 129(1-3):252-260.
35. Canuso CM, Battisti WP. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. Expert Opin Pharmacother. 2010;11(15):2557-2567.